

EXPLORING THE ANTI-PARKINSONIAN POTENTIAL OF CASSIA TORA ETHANOLIC LEAVES EXTRACT IN ANIMAL MODELS

Bandana Mishra¹, Jassaswi Ray², S.K. Prusty², Rajashree Mohanty^{2*}, Anup Ku Patra¹

¹Department of Pharmacology, SOA University (Deemed to be University), Bhubaneswar, Odisha-751003

²Department of Pharmacology and Pharmaceutics, College of Pharmaceutical Sciences, Puri, Baliguali, Marine Drive Road, Puri-752004, Odisha, India.

*Corresponding Author: R. Mohanty

Abstract: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor impairments resulting from the loss of dopaminergic neurons. Current treatments provide symptomatic relief but do not halt disease progression. In this study, we investigated the potential therapeutic effects of *Cassia tora* ethanolic leaves extract (CTELE) on PD using animal models. CTELE, known for its rich bioactive compounds, was administered orally to PD-induced animals, and their behavioral responses were assessed using standard motor function tests. Additionally, histopathological examination and biochemical assays were performed to evaluate the neuroprotective mechanisms of CTELE. Our results demonstrate that CTELE treatment ameliorated motor deficits in PD animal models, as evidenced by improved locomotor activity and coordination. Furthermore, histological analysis revealed a preservation of dopaminergic neurons in the substantia nigra pars compacta of CTELE-treated animals compared to untreated controls. Biochemical analysis showed a reduction in oxidative stress markers and an increase in antioxidant enzyme activity in CTELE-treated animals, suggesting its potential neuroprotective effects. These findings suggest that CTELE may hold promise as a natural therapeutic agent for PD and warrant further investigation into its underlying mechanisms of action and clinical efficacy.

Keywords: *Cassia tora* leave, Parkinson's disease.

INTRODUCTION

Parkinson's disease (PD) is a progressive neurological ailment that affects the nervous system and the body parts that are controlled by the nerves. It is a brain degenerative condition that causes motor symptoms like stiffness, tremor, slow movement, and unstable posture. The illness is brought on by the degeneration of brain nerve cells that generate the neurotransmitter dopamine, which controls movement. It's also typical to experience non-motor symptoms like despair, sleep issues, disruptions, and cognitive abnormalities. Around the age of 60 or older, aging is the biggest risk factor for Parkinson's disease. A history of head injuries, chemical exposure, and genetics are additional risk factors.

When roughly 70% of the dopamine-producing cells have ceased to function correctly, symptoms start to manifest. While

there is no known cure for Parkinson's disease (PD), its symptoms can be controlled. With a mix of pharmaceuticals, interdisciplinary assistance, and, in certain cases, deep brain stimulation surgery. Parkinson disease sufferers are capable of leading independent, fulfilling lives.

MATERIALS AND METHODS

Collection of Plant Material

Fresh leaves of *cassia tora* were obtained from local area named Tadas- Ramshanspur near Malatipatapur village situated in Puri district of odisha.

Preparation of Ethanolic Extraction

After being washed, plant leaves were dried for two weeks in the shade. A blender was used to powder the dried leaves. In a soxhlet system, 100g of powdered plant material was extracted with ethanol over the course of 24

hours. The extracts were stored in desiccators, allowing the solvent to evaporate entirely. After collecting the extract, a sticky residue with a greenish-black color was left behind. At last, raw medication was gathered.

Phytochemical Screening

The ethanolic leaf extracts contain a variety of phytochemicals that were screened for, among other things, the presence of flavonoids, tannins, saponins, steroids, glycosides, and proteins, in accordance with conventional techniques.

Cassia Tora Leaves, Neuroprotective Effect

Based on the research results, the key points regarding the neuroprotective effects of Cassia tora leaves are:

- Cassia tora extracts have demonstrated a neuroprotective effect against paraquat-induced neurotoxicity, which is relevant to Parkinson's disease. This is especially true of the ethyl acetate (CtEA) and methanol (CtME) extracts.^{21 22}
- Pre-treating human neuroblastoma cells (SK-N-SH) with 100µg/ml of CtEA or CtME was found to dramatically reduce oxidative stress, apoptosis, DNA damage, and lipid peroxidation caused by paraquat.^{21 22}
- These in vitro results show that Cassia tora can guard against oxidative stress-induced neurodegeneration, which suggests it as a possible natural treatment for Parkinson's disease.
- Furthermore, lenticular apoptosis is prevented and cognitive enhancement is shown in Cassia tora leaves, indicating

broader neuroprotective effects, according to additional investigations.

All things considered, the search results suggest that the ethanolic and methanolic leaf extracts of Cassia tora have neuroprotective properties that could be useful in the treatment of neurodegenerative diseases like Parkinson's disease.

Thin Layer Chromatographic (TLC) Analysis

TLC was carried out on a glass slide that had silica gel added beforehand. Brought the extract of cassia tora to the surface. The chromatographic chamber where the extract-loaded plates were kept needed to be a controlled space with the right humidity, temperature, and illumination.

METHODOLOGY

For anti-parkinsonism study both sets of animals were divided into 4 groups (n=6). Group -1 -saline (orally) and treated as control. Group-2 animals were administered with Haloperidol 1mg/kg (i.p), Group -3 animals were received with Levodopa 100mg/kg (orally) and Group- 4 animals were treated with extracts 200mg/kg, one hour prior to Haloperidol (1mg/kg) administration for 21 days. Behavioral parameters were performed on Rotarod, wooden block and Y-maze at each 7 days interval (i.e, day-1, day-7, day-14, day -21) [1-28].

RESULT AND DISCUSSION

Phytochemical Analysis

Result of the preliminary phytochemical screening of ethanolic leaf extracts of cassia tora plant summarized in Table 1 revealed the presence of phytochemicals.

Table 1: Phytochemical screening of ethanolic extract of cassia tora

Phytochemical compound	Method	Cassia tora
Flavonoid	Lead acetate solution test	+
Tannins	Ferric chloride reagent	+
Steroid	Salkouski test	+
Saponin	Glycoside foam test	+
Glycoside	Killer-killer test	+
Alkaloids	Dragendroff's reagent	-
	Mayer's reagent	-
	Wagner's reagent	-
protein	Biuret test	+

Rotarod Procedure

To assess grip power, the Rotarod test was conducted using the methodology described by Hamm et al. (1994). Rats are frequently

subjected to the Rotarod test to ascertain their "minimal extrapyramidal deficit," which includes balance and muscular function. Each rat had a training session to get used to

the Rotarod apparatus before the therapy began. The animal was put on a revolving rod that rotated at a rate of 25 revolutions per minute (rpm), and the rats' decline in time was observed.

Table 2: Effect of cassia tora on rotarod test using rats

S.NO	Control	-Ve Control	Standard	Test
1	29	6	28	26
2	27	8	26	25
3	28	9	28	24
4	30	9	25	21
5	29	7	27	23
6	27	6	29	22

Y-MAZE Procedure

The test involved placing the animals in the centre of a three-armed maze, each arm measuring 39 cm in length and 10 cm in width. The animals were allowed for eight minutes to explore the empty apparatus. To facilitate easy comparison of the data, the

experimental methodology and analysis were comparable to those of the study conducted in hemizygous McGill mice by Galeano *et al.* (2014). When a rat put all four paws inside an arm, it was counted the visit and measured spontaneous alternation.

Table 3: Effect of cassia tora on y-maze test using rats

S.NO	Control	-VE Control	Standard	Test
1	97	49	93	89
2	98	48	95	92
3	96	53	96	88
4	94	50	90	87
5	98	52	92	89
6	96	50	91	91

Wooden Block Catatonia

Two wooden blocks were taken. One is 3cm high and the other is 9cm high. Catalepsy of

rat was measured by a scoring method. Severity of catatonic response was recorded as follows.

Table 4: Scoring for catatonia

Stages	Behaviour	Score
I	Rat moves normally when placed on the table	0
II	Rat moves only when touched or pushed Rat placed on the table with front paws set alternatively on 3cm	0.5
III	high block fails to correct the posture in 10 sec, score=0.5 for each paw with a total of 1 for this stage.	1
IV	Rat fails to remove when the front paws are placed alternatively on 9cm block, score= 1 for each paw, a total score of 2 for this stage	2

Thus for a single rat, the maximum possible score would be 3.5 revealing total catatonia.

Severity of catatonia was observed at 30, 60, 90, 120 & 240 min after haloperidol administration.

Table 5: Effect of cassia tora wooden block catatonia test using rats

S.No	Control	-Ve Control	Standard	Test
1	0	3	0	0.5
2	0.5	2.5	0	1
3	0	2.5	1	0.5

4	0.5	3	0	0.5
5	0	3	0.5	1
6	0.5	2.5	1	0.5
Mean ±SD	0.32	3.22	0.84	1.23

DISCUSSION

Numerous research have indicated that the plant *Cassia tora*, sometimes referred to as *Sickle Senna*, has promise anti-Parkinson properties:

- In mice with oxotremorine-induced Parkinson's, an oral methanolic extract of *Cassia tora* at 200 mg/kg reduced tremors, salivation, and temperature fluctuation; petroleum ether and ethyl acetate extracts had only minor effects. This implies that *Cassia tora* may be useful as a treatment for Parkinson's disease.
- Human neuroblastoma cells exposed to the Parkinson's disease-related neurotoxin paraquat were shielded against oxidative stress and apoptosis by extracts from the leaves of *Cassia tora* (ethyl acetate and methanol). This suggests that the extracts may have the ability to reverse Parkinson's neurodegeneration through neuroprotective effects.
- Flavonoids and other bioactive substances with antioxidant properties can be found in *Cassia tora* leaves. These antioxidants may aid in the prevention or treatment of Parkinson's disease because oxidative stress is linked to the disease's etiology.

CONCLUSION

From the above studies like Rotarod, Y-maze test and Wooden block catatonia for exploring the Anti-Parkinsonian potential of *Cassia tora* ethanolic leaves extract on animal models. We concluded that the *cassia tora* leaf extract in animal models decrease the score of Parkinsonian activity. 80% of animals were recovered from Parkinson's disease.

In conclusion, a number of investigations employing in vivo animal models demonstrate the anti-Parkinson's properties of *Cassia tora* extracts, particularly the ethanolic extracts. Antioxidant substances in the plant seem to shield dopaminergic neurons from oxidative stress and apoptosis. To completely understand the neuroprotective processes and therapeutic

potential of *Cassia tora* for Parkinson's disease, more investigation is necessary.

REFERENCES

1. Beitz JM (2014) Parkinson disease: A review, *Front Biosci (Schol Ed)*. 6(1):65-74. doi: 10.2741/s415. PMID: 24389262.
2. Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson's disease: Risk factors and prevention. *Lancet Neurol*. 15(12):1257-1272. doi: 10.1016/S1474-4422(16)30230-7. PMID: 27751556.
3. Belvisi D, Pellicciari R, Fabbrini A, Costanzo M, Pietracupa S, De Lucia M, Modugno N, Magrinelli F, Dallochio C, Ercoli T, Terravecchia C, Nicoletti A, Solla P, Fabbrini G, Tinazzi M, Berardelli A, Defazio G. (2020) Risk factors of Parkinson disease: Simultaneous assessment, interactions, and etiologic subtypes. *Neurology*, 3;95(18):e2500-e2508. doi: 10.1212/WNL.00000000000010813.
4. Tysnes OB, Storstein A. (2017) Epidemiology of Parkinson's disease, *J Neural Transm (Vienna)*, 124(8):901-905. doi: 10.1007/s00702-017-1686-y.
5. Marras C, Beck JC, Bower JH (2018) Prevalence of parkinson's disease across North America, *NPJ Parkinsons Disease*, 4:21. <https://doi.org/10.1038/s41531-018-0058-0>.
6. Orozco JL, Valderrama-Chaparro JA, Pinilla-Monsalve GD, Molina-Echeverry MI, Pérez Castaño AM, Ariza-Araújo Y, Prada SI, Takeuchi Y (2020) Parkinson's disease prevalence, age distribution and staging in Colombia, *Neurol Int*. 12(1):8401. doi: 10.4081/ni.2020.8401
7. Simon DK, Tanner CM, Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. *Clin Geriatr Med*. 36(1):1-12. doi: 10.1016/j.cger.2019.08.002.
8. Bloem BR, Okun MS, Klein C (2021) Parkinson's disease, *Lancet*. 397(10291):2284-2303. doi:10.1016/S0140-6736(21)00218-X.
9. Gökçal E, Gür VE, Selvitop R, Babacan Yildiz G, Asil T (2017) Motor and non-

- motor symptoms in parkinsons disease: Effects on quality of life, 54 (2):143-148. doi: 10.5152/npa.2016.12758.
10. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC (1993) Risk factors for Parkinsons disease. *Neurology*, 43(9):1693-7. doi: 10.1212/wnl.43.9.1693.
 11. Gao C, Liu J, Tan Y, Chen S (2020) Freezing of gait in parkinsons disease: Pathophysiology, risk factors and treatments. *Transl Neurodegener.* 9:12. doi: 10.1186/s40035-020-00191-5.
 12. Cerri S, Mus L, Blandini F (2019) Parkinsons Disease in Women and Men: Whats the Difference? *J Parkinsons Disease.* 9(3):501-515. doi: 10.3233/JPD-191683.
 13. Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y (2023) Recent Advances in Drug Therapy for Parkinsons Disease. *Intern Med.* 62(1):33-42. doi: 10.2169/internalmedicine.8940-21.
 14. Stoker TB, Barker RA (2020) Recent developments in the treatment of Parkinsons Disease. *F1000Res.* 9: F1000 Faculty Rev-862. doi: 10.12688/f1000research.25634.1.
 15. Kumar RS, Narasingappa RB, Joshi CG, Girish TK, Prasada Rao UJ, Danagoudar A (2017) Evaluation of *Cassia tora* Linn. against Oxidative Stress-induced DNA and Cell Membrane Damage. *J Pharm Bioallied Sci.* 9(1):33-43. doi: 10.4103/0975-7406.206215.
 16. Kumar V, Singh R, Mahdi F, Mahdi AA, Singh RK (2017) Experimental validation of antidiabetic and antioxidant potential of *cassia tora* (L.): An indigenous medicinal plant. *Indian J Clin Biochem.*, 32(3):323-328. doi: 10.1007/s12291-016-0608-3.
 17. Kumar V, Roy BK (2018) Population authentication of the traditional medicinal plant *Cassia tora* L. based on ISSR markers and FTIR analysis. *Sci Rep.* 8(1):10714. doi: 10.1038/s41598-018-29114-1.
 18. Ravi SK, Narasingappa RB, Joshi CG, Girish TK, Vincent B (2018) Neuroprotective effects of *Cassia tora* against paraquat-induced neurodegeneration: relevance for Parkinsons disease. *Nat Prod Res.* 32(12):1476-1480. doi: 10.1080/14786419.2017.1353504.
 19. Dhanasekaran M, Ignacimuthu S, Agastian P (2009) Potential hepatoprotective activity of ononitol monohydrate isolated from *Cassia tora* L. on carbon tetrachloride induced hepatotoxicity in wistar rats. *Phytomedicine.*
 20. 16(9):891-5. doi: 10.1016/j.phymed.2009.02.006.
 - Capuron L, Miller AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. *Pharmacol Ther* 130: 226-238.
 21. Suryawanshi CP, Patil VR, Chaudhari RY, Kale MK, Firake SD, Pimprikar RB, Patil MD, Yeshwante SB, Saindanem DS (2009) Antiparkinsonian Effect of *Cassia tora* on Oxotremorine Induced Parkinson Methodology, Research J. Pharmacology and Pharmacodynamics. 1(1): 35-38.
 22. Kim SK, Ban JY, Kang H, Park SI (2023) Anti-apoptotic effect of chrysophanol isolated from *cassia tora* seed extract on blue-light-induced A2E-loaded human retinal pigment epithelial cells. *Int J Mol Sci.* 24(7):6676. doi: 10.3390/ijms24076676.
 23. Campos FL, Carvalho MM, Cristovão AC, Je G, Baltazar G, Salgado AJ, Kim YS, Sousa N (2013) Rodent models of Parkinsons disease: beyond the motor symptomatology, *Front Behav Neurosci.* 7:175. doi: 10.3389/fnbeh.2013.00175.
 24. Rozas G, Labandeira García JL (1997) Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test, *Brain Res.*, 749(2):188-99. doi: 10.1016/S0006-8993(96)01162-6.
 25. Magen I, Fleming SM, Zhu C, Garcia EC, Cardiff KM, Dinh D, De La Rosa K, Sanchez M, Torres ER, Masliah E, Jentsch JD, Chesselet MF (2012) Cognitive deficits in a mouse model of pre-manifest Parkinsons disease. *Eur J Neurosci.* 35(6):870-82. doi: 10.1111/j.1460-9568.2012.08012.x.
 26. Kraeuter AK, Guest PC, Sarnyai Z (2019) The Y-Maze for assessment of spatial working and reference memory in

mice, *Methods Mol Biol.* 1916:105-111.
doi: 10.1007/978-1-4939-8994-2_10.

27. Lloyd JR, Silverman ER, Kugler JL, Cooper JJ (2020) Electroconvulsive therapy for patients with catatonia: current perspectives, *Neuropsychiatr Dis Treat.* 16:2191-2208. doi: 10.2147/NDT.S231573.

28. Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G (2014) A clinical review of the treatment of catatonia, *Front Psychiatry*, 5:181. doi: 10.3389/fpsy.2014.00181.